CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Miromatrix Medical Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Miromatrix Medical Inc
6455 Flying Cloud Drive, Suite 107
Phone: (612) 202-7026p:612 202-7026 EDEN PRAIRIE, MN  55344  United States Fax: (302) 655-5049f:302 655-5049

This company was Merged or Acquired on 12/13/2023.
This company ceased filing statements with the SEC on 12/26/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Miromatrix Medical Inc. is a life sciences company. The Company is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreas. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. Its product pipeline includes miroliverelap, mirokidney, miroliver, miroheart, mirolung and miropancreas.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board PaulBuckman 67 4/1/2017 4/1/2017
Chief Executive Officer, Director JeffreyRoss 46 1/1/2017 1/1/2017
Chief Financial Officer, Secretary JamesDouglas 49 3/1/2022 3/1/2022
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 76 (As of 3/20/2023)
Outstanding Shares: 27,419,228 (As of 11/9/2023)
Shareholders: 193
Stock Exchange: NASD
Federal Tax Id: 271285782
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, March 27, 2024